Identification of DR9-restricted XAGE antigen on lung adenocarcinoma recognized by autologous CD4 T-cells

MICHIHIDE SHIMONO1,2, AKIKO UENAKA1, YUJI NOGUCHI1, SHUICHIRO SATO3, HIDEOKUMURA3, KAZUHIKO NAKAGAWA3, KATSUYUKI KIURA2, MITSUNE TANIMOTO2 and EIICHI NAKAYAMA1

Departments of 1Immunology, 2Internal Medicine II, and 3Surgery II, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama 700-8558, Japan

Received November 13, 2006; Accepted December 28, 2006

Abstract. We previously demonstrated a dominant IgG response against XAGE-1b antigen in a lung cancer patient by serological analysis of antigens by recombinant expression cloning (SEREX) analysis using a cDNA library from the autologous OU-LU-6 tumor cell line. In this study, we investigated recognition of XAGE-1b on OU-LU-6 tumor by the patient CD4-expressing tumor-infiltrating lymphocytes (CD4 TIL). The response of CD4 TIL obtained from malignant pleural effusion was determined against autologous OU-LU-6 tumor cells and XAGE-1b mRNA-transfected PHA-stimulated CD4 T-cells (T-APC) from healthy individuals sharing HLA-DR with the patient by performing IFN-γ secretion and ELISPOT assays. The patient CD4 TIL recognized OU-LU-6 in an HLA-DR-restricted manner and XAGE-1b mRNA-transfected T-APC derived from DRB1*0901-sharing healthy donor (HD1) and HD2, but not DRB1*1101-sharing HD3 or HD4. Epitope analysis using 17 18-mer peptides with 12 overlapping amino acids revealed that the CD4 TIL recognized XAGE-1b 33-49. The findings suggest that the patient CD4 T-cells recognized the XAGE-1b 33-49-related epitope on autologous OU-LU-6 tumor cells in a manner restricted by DR*0901.

Introduction

XAGE-1 was originally identified by a search for PAGE/GAGE-related genes using an expressed sequence tag database (1) and was shown to exhibit characteristics of cancer/testis (CT)-like antigen (2). Four transcript variants, XAGE-1a, XAGE-1b, XAGE-1c, and XAGE-1d, have been identified and were shown to be expressed in metastatic melanoma, Ewing’s sarcoma, and various epithelial tumors such as breast, lung, and prostate cancers (3-5). We recently demonstrated that XAGE-1b mRNA was a dominantly expressed transcript and was detected in 15 of 49 (31%) lung cancer specimens (6). Histologically, its expression was observed in 14 of 31 (45%) adenocarcinomas and 1 of 18 (6%) lung cancers of other types. Immunohistochemical (IHC) analysis using a XAGE-1 monoclonal antibody (mAb) showed that most of the XAGE-1b mRNA-positive specimens expressed XAGE-1 protein. Seropositivity was observed in 5 of 56 (9%) patients with adenocarcinoma, whereas none of 18 patients with lung cancers of other types produced XAGE-1b antibody. Thus, it was shown that XAGE-1b is expressed in a significant proportion of lung adenocarcinomas and is immunogenic in patients.

In the serological analysis of antigens by SEREX, we previously identified XAGE-1b as a dominant antigen using serum from a lung adenocarcinoma patient by screening a cDNA library from an autologous OU-LU-6 tumor cell line established from malignant pleural effusion (7). In this study, we investigated the response of CD4 TIL in malignant pleural effusion of a patient against an autologous OU-LU-6 tumor. The patient CD4 TIL were shown to produce IFN-γ in response to the autologous tumor and their recognition was restricted to HLA-DR. The T-cells produced IFN-γ-ELISPOTs in response to XAGE-1b mRNA-transfected T-APC from HD sharing HLA-DRB1*0901 with the patient. Furthermore, the peptide epitope recognized by the T-cells was shown to be XAGE-1b 33-49.

Materials and methods

Patient characteristics and clinical course. Patient OU-LU-6, a 38-year-old Japanese man had back pain and visited Okayama University Hospital in September 1999. He was found to have a large hilar mass and enlarged lymph nodes in his neck. A lymph node biopsy specimen was diagnosed pathologically as poorly differentiated adenocarcinoma in October 1999. The patient developed multiple metastases in the liver and malignant pleural effusion in November 1999. Malignant pleural effusion and serum were obtained with written informed consent in February 2000. The patient died due to respiratory failure in March 2000.

Tumor cell lines. OU-LU-6, OU-LU-17, OU-LU-26, OU-LC-MS and OU-LC-KI are lung adenocarcinoma cell lines established in our laboratory. Lung cancer cell lines 11-18 and...
PC-9 have been described (8). K562 is a myeloid leukemia cell line (9). EBV-HD1 and 3 are Epstein-Barr virus (EBV)-transformed B-cell lines from HD. Those cell lines were maintained in RPMI-1640 medium (Gibco, Rockville, MD) supplemented with 10% FCS (Sigma-Aldrich, St. Louis, MO).

HLA class I and class II genotypes of the tumor cell lines and HD cells were determined as described previously (10) and are listed in Table I.

**Table I. HLA genotypes.**

<table>
<thead>
<tr>
<th></th>
<th>A</th>
<th>B</th>
<th>C</th>
<th>DRB1</th>
</tr>
</thead>
<tbody>
<tr>
<td>OU-LU-6</td>
<td>*0201</td>
<td>*3501/*4002</td>
<td>*0303/*0304</td>
<td>*0901/*1101</td>
</tr>
<tr>
<td>OU-LU-17</td>
<td>*2402/*2602</td>
<td>*1501/*4001</td>
<td>*0303/*0802</td>
<td>ND</td>
</tr>
<tr>
<td>OU-LU-26</td>
<td>*0201/*2402</td>
<td>*5201/*6701</td>
<td>*0702/*1202</td>
<td>ND</td>
</tr>
<tr>
<td>OU-LC-MS</td>
<td>*2601</td>
<td>*4601</td>
<td>*0303/*1601</td>
<td>ND</td>
</tr>
<tr>
<td>OU-LC-KI</td>
<td>*0201/*0206</td>
<td>*3901</td>
<td>*0304/*1402</td>
<td>ND</td>
</tr>
<tr>
<td>11-18</td>
<td>*0201/*2402</td>
<td>*5201/*5401</td>
<td>*0102/*1201</td>
<td>ND</td>
</tr>
<tr>
<td>PC-9</td>
<td>*0206/*2402</td>
<td>*3901</td>
<td>*0303/*0702</td>
<td>ND</td>
</tr>
<tr>
<td>HD1</td>
<td>*1101/*2402</td>
<td>*4002/*4006</td>
<td>*0304</td>
<td>*0901/*1502</td>
</tr>
<tr>
<td>HD2</td>
<td>*0206/*2402</td>
<td>*3501/*5401</td>
<td>*0102/*0303</td>
<td>*0901/*1401</td>
</tr>
<tr>
<td>HD3</td>
<td>*0201/*2402</td>
<td>*1501/*5201</td>
<td>*0304</td>
<td>*1101/*1502</td>
</tr>
<tr>
<td>HD4</td>
<td>*0201/*2402</td>
<td>*1501/*5201</td>
<td>*0401/*1202</td>
<td>*0403/*1406</td>
</tr>
</tbody>
</table>

ND, not done

Preparation of dendritic cells (DC). Monocytes were isolated from peripheral blood mononuclear cells (PBMC) using anti-CD14 mAb-coated magnetic beads (MACS; Miltenyi Biotec, Auburn, CA) and cultured in RPMI-1640 medium supplemented with 10% human AB serum (Sigma-Aldrich), 10 ng/ml recombinant human (rh) GM-CSF (Kirin Brewery, Tokyo, Japan) and 10 ng/ml rhIL-4 (PeproTech, London, UK) for one week. Lipopolysaccharide (LPS) (Sigma-Aldrich) was added at 100 ng/ml on day 6 to induce maturation of DC. On day 7, DC were harvested.

Generation of PHA-stimulated CD4 T-cells (T-APC). CD4 T-cells purified using anti-CD4 mAb-coated magnetic beads (MACS) were cultured in RPMI-1640 medium supplemented with 10% human AB serum and 10 μg/ml phytohemagglutinin-L (PHA) (Sigma-Aldrich). On day 3, half of the medium was replaced with the medium containing rhIL-2 (20 IU/ml) (Takeda Pharmaceutical, Osaka, Japan) and rhIL-7 (20 ng/ml) (PeproTech) and this was repeated twice a week (11).

Electroporation of mRNA. This was done as described (12). After adding mRNA (10 μg) at room temperature, T-APC were pulsed at 400 V for 480 μs in a 0.2-cm-gap electroporation cuvette (200 μl) using an electrophorator square porator (model ECM830; BTX, Holliston, MA).

Isolation and culture of TIL. Malignant pleural effusion was drawn in heparin. Tumors and TIL were collected by density gradient centrifugation (13). Tumor cells formed a band on the top of 75% (density 1.055) Histopaque 1077 (Sigma-Aldrich) and a TIL-enriched fraction formed a band at the interface between 75% and 100% (density 1.077) Histopaque 1077.

TIL were maintained in AIM-V medium (Gibco) supplemented with 10% human AB serum and rhIL-2 (20 IU/ml) at a concentration of 0.5-2x10^6 cells/ml by weekly stimulation.
described previously (14). T-cells (5x10^4) and irradiated (2x10^4) or irradiated (30 Gy) T-APC (1x10^4) as target cells in 37˚C. CD4 T-cells (2x10^6) were cultured with irradiated medium (Cambrex BioScience, Walkersville, MD) for 2 h at 37˚C. After washing extensively, (1x10^4) were cultured with irradiated (100 Gy) tumor cells mAb (1-D1K) in PBS overnight at 4˚C. Responding T-cells IFN\(_\text{\alpha}\) was purchased from PeproTech. IFN\(_\text{\alpha}\) 51Cr-release assay as described previously (8).

In vitro stimulation of CD4 T-cells with peptides. For peptide pulse, cells were incubated with 10^7 M peptide in X-VIVO 15 medium (Cambrex BioScience, Walkersville, MD) for 2 h at 37˚C. CD4 T-cells (2x10^6) were cultured with irradiated (30 Gy) peptide-pulsed DC (5x10^5) in AIM-V medium with 10% heat-inactivated pooled human serum. After a 1-week culture, responding CD4 T-cells were re-stimulated with autologous DC pulsed with the corresponding peptide. rHL-2 (10 IU/ml) was added on the next day. For the third stimulation, irradiated (30 Gy), peptide-pulsed autologous T-APC were used as antigen presenting cells. The cultures were supplemented with 20 IU/ml rHL-2 1 day after the third stimulation.

Flow cytometry analysis. For surface antigen staining, 5 μl of mAbs were added for every set of 1x10^6 cells. After incubation for 30 min, cells were washed twice with 2 ml of PBS and fixed with 500 μl of fixation buffer containing 0.5% paraformaldehyde. The cells were analyzed in a FACSscan (Becton Dickinson, San Jose, CA) using Cell Quest software (Becton Dickinson).

Cytotoxicity assay. Cytotoxicity of the T-cells was tested in a ^51^Cr-release assay as described previously (8).

IFN\(_\text{\gamma}\) ELISA assay. The IFN\(_\text{\gamma}\) ELISA assay was performed as described previously (14). T-cells (5x10^4) and irradiated (100 Gy) EBV-B cells (5x10^4) or tumor cells (2x10^4) were cultured in X-VIVO 15 medium in round-bottom 96-well plates for 20 h at 37˚C. After culturing, the supernatant was harvested and the level of IFN\(_\text{\gamma}\) was measured. Standard IFN\(_\text{\gamma}\) was purchased from PeproTech.

IFN\(_\text{\gamma}\) ELISPOT assay. ELISPOT 96-well plates (Millipore, Bedford, MA) were coated with 5 μg/ml anti-human IFN\(_\text{\gamma}\) mAb (1-D1K) in PBS overnight at 4˚C. Responding T-cells (1x10^6) were cultured with irradiated (100 Gy) tumor cells (2x10^4) or irradiated (30 Gy) T-APC (1x10^5) as target cells in X-VIVO 15 for 20 h at 37˚C. After washing the wells, rabbit anti-human IFN\(_\text{\gamma}\) serum (diluted 1:800 with PBS) was added and incubated for 2 h at 37˚C. After washing extensively, AP-conjugated goat anti-rabbit IgG (diluted 1:2,000 with PBS) was added and incubated for 1 h at 37˚C. After washing, substrate (AP conjugate substrate kit: Bio-Rad Laboratories, Hercules, CA) was added and incubated for 20 min at room temperature. Spots were counted under a microscope after washing the plates.

**Results**

Characterization of lung cancer cell line OU-LU-6. Lung cancer cell line OU-LU-6 was established from malignant pleural effusion of a lung adenocarcinoma patient and maintained for >5 years. As shown in Fig. 1, OU-LU-6 cells express both HLA class I and class II, and CD40 and CD95 antigens. No expression of CD80 and CD86 was observed.

Establishment of autologous TIL line against OU-LU-6. TIL and tumor cells were obtained from pleural effusion by density gradient centrifugation. TIL were maintained in AIM-V medium supplemented with 10% human AB serum and IL-2 (20 IU/ml) by weekly stimulation with irradiated autologous OU-LU-6 as a bulk TIL line (Fig. 2A). CD4 T-cells were purified using anti-CD4 mAb-coated magnetic beads and maintained similarly to the bulk TIL. As shown in Fig. 2B, CD4-expressing TIL (CD4 TIL) produced IFN\(_\text{\gamma}\) upon stimulation with OU-LU-6, but not with 6 other lung cancer cell lines including OU-LU-17, OU-LU-26, OU-LC-MS, OU-LC-KI, 11-18 and PC-9, nor EBV-transformed HD1 or HD3 B-cell lines. No expression of HLA class II antigens was observed on the 6 tumor cell lines by FACS analysis (data not shown). As shown in Fig. 2C, the production of IFN\(_\text{\gamma}\) by CD4 T-cells was blocked by the addition of anti-CD4 mAb, anti-HLA class II mAb and anti-HLA-DR mAb, but not anti-CD8 mAb, anti-HLA class I mAb, anti-HLA-DR mAb or anti-HLA-DQ mAb to the assay culture. These findings suggested HLA-DR restricted recognition of OU-LU-6 by the patient CD4 T-cells.

We previously demonstrated a dominant IgG response against XAGE-1b antigen in the patient from whose pleural effusion OU-LU-6 was established by SEREX analysis using autologous sera and confirmed XAGE-1b expression on OU-LU-6 by RT-PCR (6). CD4 T helper cells stimulated XAGE-1b peptide-pulsed DC (5x10^4) in AIM-V medium with 10% heat-inactivated pooled human serum. After a 1-week culture, responding CD4 T-cells were re-stimulated with autologous sera and confirmed antibody production. Therefore, we investigated whether the patient bulk CD4 T-cells recognized XAGE-1b in a DR-restricted manner. For this, we used XAGE-1b mRNA-transfected T-APC obtained from normal individuals with various DR types as target cells. T-APC have previously been shown to express HLA class I, class II and CD86 (12). As shown in Fig. 2D, the patient bulk CD4 TIL line maintained by stimulation with OU-LU-6 in fact recognized XAGE-1b in a manner restricted to DRB1*0901.

Epitope analysis. The epitope peptides recognized by the bulk CD4 T-cells were analyzed using 17 18-mer peptides with 12 overlapping amino acids using HD1 (DRB1*0901) EBV-B cells as APC. As shown in Fig. 3A, peptide 9 was recognized by bulk CD4 T-cells. Peptide 8 was weakly recognized. The minimal epitope sequence was then determined with the peptide 9 using C- and N-termini truncated peptides. The response of the bulk CD4 T-cells was tested against peptide-
pulsed HD1 T-APC (DRB1*0901) by the IFNγ ELISPOT assay. As shown in Fig. 3B, truncation of 4 amino acids from the C-terminus caused loss of the stimulatory activity, while the truncation of 1 amino acid from the N-terminus caused loss of the stimulation. Thus, the minimal epitope sequence recognized by the bulk CD4 T-cells is likely to be XAGE-1b 33-46.

Recognition by HD1 CD4 T-cells stimulated with peptide 9 of XAGE-1b mRNA-transfected autologous DC. HD1 CD4 T-cells were purified using anti-CD4 mAb-coated magnetic beads and stimulated with XAGE-1b 33-49 (peptide 9)-pulsed autologous DC twice and then T-APC once weekly and tested for recognition of the peptide by the IFNγ ELISPOT assay. As shown in Fig. 4, recognition by the CD4 T-cells of XAGE-1b 33-49 was observed. Recognition of XAGE-1b mRNA-transfected autologous T-APC was then examined. XAGE-1b mRNA-transfected, but not untransfected autologous T-APC were recognized, suggesting that the XAGE-1b 33-49 (peptide 9)-related epitope was processed naturally.

Discussion

We previously demonstrated that a dominant IgG response was observed against XAGE-1b in a lung cancer patient by SEREX analysis using a cDNA library from the autologous OU-LU-6 tumor cell line. In this study, we showed that the patient CD4 TIL obtained from malignant pleural effusion produced IFNγ in response to autologous OU-LU-6 tumor. The response was blocked in an HLA-DR-restricted manner. The patient CD4 TIL produced IFNγ in response to XAGE-1b mRNA-transfected T-APC derived from DRB1*0901-sharing, but not DRB1*1101-sharing normal individuals. These findings suggested that the patient CD4 T-cells recognized XAGE-1b antigen on OU-LU-6 tumor cells in a manner restricted by DRB1*0901. Epitope analyses using 17 18-mer peptides with 12 overlapping amino acids revealed that the CD4 TIL recognized XAGE-1b 33-49. The minimal peptide sequence recognized by the CD4 T-cells was determined to be XAGE-1b 33-46 by using N- and C-terminal truncated peptides. Furthermore, stimulation of DRB1*0901-positive HD1 CD4 T-cells with XAGE-1b 33-49 peptide resulted in recognition of the peptide-pulsed and XAGE-1b mRNA-transfected autologous T-APC, suggesting that XAGE-1b 33-49-related epitope was processed naturally.

The IgG response results from the activation of CD4 T helper cells. The findings that CD4 TIL in the patient recognized XAGE-1b antigen on the OU-LU-6 cell surface in a manner restricted by DR suggested that the dominant IgG
response to XAGE-1b antigen shown in this patient by SEREX analysis (7) resulted from the activation of CD4 T-cells against the same antigen. HLA class II antigen expression was observed on OU-LU-6. This may greatly facilitate the activation of CD4 T-cells and may have resulted in the vigorous antibody response observed in this patient. In this regard, it should be further investigated whether serum antibody response against the tumor antigen in the patient was related to the expression of HLA class II antigen on the tumor with the relevant antigen.

XAGE-1b mRNA expression is observed at a significant frequency in lung (15/49, 31%) (6), liver (13/39, 33.3%), and prostate (14/54, 25.9%) cancers, and at a low frequency in breast cancer (1/20, 5%). On the other hand, XAGE-1b protein expression has been observed only in lung cancer, with most lung cancers expressing XAGE-1b mRNA, with a few exceptions, as shown by IHC using USO 9-13 mAb. Moreover, the patients who showed an antibody response against XAGE-1b antigen were those with lung cancer (6). These findings suggest that XAGE-1b expression is unique to lung cancers. Among lung cancers, its expression was mostly observed in adenocarcinomas.

Expression of CT antigens was observed at a high frequency in lung cancers (15). Among CT antigens, MAGE-A3 is one of the most commonly expressed, but a spontaneous humoral immune response to the antigen is rarely observed in patients (16). NY-ESO-1 is less frequently expressed, but has been shown to induce frequent and spontaneous antibody, CD4, and CD8 T-cell responses in a Caucasian population of patients (17,18). However, in the Japanese population, the frequency of NY-ESO-1 expression is low (~5%) in lung cancer, comparing to a frequency of ~30% in Caucasians. We observed antibody production against XAGE-1b in 5 of 56 patients with adenocarcinoma but not in 18 patients with other histological types or 40 healthy donors. These findings indicated that XAGE-1b expressed in lung adenocarcinoma was strongly immunogenic in patients. XAGE-1b may therefore be a promising candidate target for immunotherapy (19).

Finally, we characterized the DRB*0901-binding XAGE-1b peptide recognized by CD4 T-cells. The finding that the DRB*0901-positive healthy donor CD4 T-cells stimulated with the peptide also recognized XAGE-1b mRNA-transfected HD1 T-APC suggested that the peptide-related epitope was the naturally processed antigen. Many CD4 and CD8 T-cell epitopes on various tumor antigens have been identified (20-23). The peptide epitope identified in this study is the first T-cell epitope defined on XAGE-1b.

Acknowledgements

We thank M. Isobe and T. Akimoto for their excellent technical assistance and J. Mizuuchi for preparation of the manuscript. This study was supported by Scientific Research on Priority Areas from the Ministry of Education, Culture, Sports, Science and Technology of Japan and the Cancer Research Institute, New York.

References


Figure 3. (A) Recognition of XAGE-1b by bulk CD4 TIL was analyzed using 17 18-mer XAGE-1b overlapping peptides. HD1 (DRB*0901) EBV-B cells were used as APC. CD4 TIL (5x10^4) were stimulated with irradiated (100 Gy), peptide (10^{-5} M)-pulsed HD1 (DRB1*0901) EBV-B cells (5x10^4 cells) in 96-well plates for 20 h and the supernatant was assayed for IFNγ by ELISA. Values are the means of duplicate cultures. (B) Minimal epitope analysis. CD4 TIL (1x10^4) were cultured with irradiated (30 Gy), peptide (10^{-5} M) pulsed HD1 T-APC (1x10^4) for 20 h in 96-well ELISPOT plates and the number of spots was counted microscopically. Values are the means of duplicate cultures.

Figure 4. HD1 CD4 T-cells (1x10^6) were cultured with irradiated (30 Gy), XAGE-1b 33-49 (peptide 9)-pulsed autologous DC (5x10^5) twice and then PHA-simulated T-APC (1x10^5) once weekly. The cells were harvested and stimulated with irradiated (30 Gy), peptide (10^{-5} M)-pulsed or XAGE-1b mRNA (10 μg)-transfected HD1 T-APC (1x10^4) in 96-well ELISPOT plates for 20 h, and the number of spots was counted microscopically. Values are the means of duplicate cultures.


